

# Yasir Waheed

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5166920/publications.pdf>

Version: 2024-02-01

133  
papers

60,588  
citations

50276  
46  
h-index

12946  
131  
g-index

139  
all docs

139  
docs citations

139  
times ranked

66829  
citing authors

#	ARTICLE	IF	CITATIONS
1	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1789-1858.	13.7	8,569
2	Global burden of 369 diseases and injuries in 204 countries and territories, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1204-1222.	13.7	7,664
3	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1736-1788.	13.7	4,989
4	Global Burden of Cardiovascular Diseases and Risk Factors, 1990â€“2019. Journal of the American College of Cardiology, 2020, 76, 2982-3021.	2.8	4,468
5	Global burden of 87 risk factors in 204 countries and territories, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1223-1249.	13.7	3,928
6	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1923-1994.	13.7	3,269
7	Global, regional, and national burden of chronic kidney disease, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2020, 395, 709-733.	13.7	2,858
8	Global, regional, and national burden of neurological disorders, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 459-480.	10.2	2,625
9	Global, regional, and national burden of stroke and its risk factors, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurology, The, 2021, 20, 795-820.	10.2	2,308
10	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1859-1922.	13.7	2,123
11	Alcohol use and burden for 195 countries and territories, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2018, 392, 1015-1035.	13.7	2,005
12	Global, regional, and national burden of stroke, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 439-458.	10.2	2,005
13	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017. JAMA Oncology, 2019, 5, 1749.	7.1	1,691
14	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. The Lancet Gastroenterology and Hepatology, 2018, 3, 383-403.	8.1	1,241
15	Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 56-87.	10.2	1,064
16	Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950â€“2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1160-1203.	13.7	890
17	The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology and Hepatology, 2020, 5, 245-266.	8.1	823
18	Global, regional, and national age-sex-specific mortality and life expectancy, 1950â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1684-1735.	13.7	716

#	ARTICLE	IF	CITATIONS
19	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet, The, 2018, 391, 2236-2271.	13.7	638
20	Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990â€“2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet, The, 2021, 397, 2337-2360.	13.7	609
21	Global, regional, and national burden of suicide mortality 1990 to 2016: systematic analysis for the Global Burden of Disease Study 2016. BMJ: British Medical Journal, 2019, 364, l94.	2.3	558
22	Global, regional, and national incidence, prevalence, and mortality of HIV, 1980â€“2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. Lancet HIV,the, 2019, 6, e831-e859.	4.7	341
23	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 2091-2138.	13.7	335
24	Five insights from the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1135-1159.	13.7	335
25	Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1250-1284.	13.7	330
26	Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017. Lancet Respiratory Medicine,the, 2019, 7, 69-89.	10.7	326
27	Population and fertility by age and sex for 195 countries and territories, 1950â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1995-2051.	13.7	294
28	Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study 2019. Lancet, The, 2021, 398, 870-905.	13.7	229
29	Global, regional, and national burden of meningitis, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2018, 17, 1061-1082.	10.2	221
30	The global burden of childhood and adolescent cancer in 2017: an analysis of the Global Burden of Disease Study 2017. Lancet Oncology, The, 2019, 20, 1211-1225.	10.7	199
31	Mapping 123 million neonatal, infant and child deaths between 2000 and 2017. Nature, 2019, 574, 353-358.	27.8	161
32	Hepatitis C virus in Pakistan: A systematic review of prevalence, genotypes and risk factors. World Journal of Gastroenterology, 2009, 15, 5647.	3.3	148
33	Mapping child growth failure across low- and middle-income countries. Nature, 2020, 577, 231-234.	27.8	128
34	Quantifying risks and interventions that have affected the burden of diarrhoea among children younger than 5 years: an analysis of the Global Burden of Disease Study 2017. Lancet Infectious Diseases, The, 2020, 20, 37-59.	9.1	104
35	Global injury morbidity and mortality from 1990 to 2017: results from the Global Burden of Disease Study 2017. Injury Prevention, 2020, 26, i96-i114.	2.4	103
36	Quantifying risks and interventions that have affected the burden of lower respiratory infections among children younger than 5 years: an analysis for the Global Burden of Disease Study 2017. Lancet Infectious Diseases, The, 2020, 20, 60-79.	9.1	95

#	ARTICLE	IF	CITATIONS
37	Measuring routine childhood vaccination coverage in 204 countries and territories, 1980â€“2019: a systematic analysis for the Global Burden of Disease Study 2020, Release 1. Lancet, The, 2021, 398, 503-521.	13.7	93
38	Global, regional, and national mortality among young people aged 10â€“24 years, 1950â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2021, 398, 1593-1618.	13.7	92
39	Mapping geographical inequalities in access to drinking water and sanitation facilities in low-income and middle-income countries, 2000â€“17. The Lancet Global Health, 2020, 8, e1162-e1185.	6.3	91
40	Hepatitis elimination by 2030: Progress and challenges. World Journal of Gastroenterology, 2018, 24, 4959-4961.	3.3	80
41	Mapping subnational HIV mortality in six Latin American countries with incomplete vital registration systems. BMC Medicine, 2021, 19, 4.	5.5	78
42	Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000â€“17: analysis for the Global Burden of Disease Study 2017. Lancet, The, 2020, 395, 1779-1801.	13.7	72
43	Mapping routine measles vaccination in low- and middle-income countries. Nature, 2021, 589, 415-419.	27.8	71
44	Global and regional burden of cancer in 2016 arising from occupational exposure to selected carcinogens: a systematic analysis for the Global Burden of Disease Study 2016. Occupational and Environmental Medicine, 2020, 77, 151-159.	2.8	64
45	The Omicron (B.1.1.529) variant of SARS-CoV-2 binds to the hACE2 receptor more strongly and escapes the antibody response: Insights from structural and simulation data. International Journal of Biological Macromolecules, 2022, 200, 438-448.	7.5	64
46	Mapping disparities in education across low- and middle-income countries. Nature, 2020, 577, 235-238.	27.8	58
47	Global and regional burden of chronic respiratory disease in 2016 arising from non-infectious airborne occupational exposures: a systematic analysis for the Global Burden of Disease Study 2016. Occupational and Environmental Medicine, 2020, 77, 142-150.	2.8	56
48	Global and regional burden of disease and injury in 2016 arising from occupational exposures: a systematic analysis for the Global Burden of Disease Study 2016. Occupational and Environmental Medicine, 2020, 77, 133-141.	2.8	56
49	Global, regional, and national sex differences in the global burden of tuberculosis by HIV status, 1990â€“2019: results from the Global Burden of Disease Study 2019. Lancet Infectious Diseases, The, 2022, 22, 222-241.	9.1	53
50	Interaction of Hepatitis C virus proteins with pattern recognition receptors. Virology Journal, 2012, 9, 126.	3.4	51
51	Prediction of promiscuous T-cell epitopes in the Zika virus polyprotein: An in silico approach. Asian Pacific Journal of Tropical Medicine, 2016, 9, 844-850.	0.8	49
52	Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017. Nature Medicine, 2020, 26, 750-759.	30.7	47
53	Public health utility of cause of death data: applying empirical algorithms to improve data quality. BMC Medical Informatics and Decision Making, 2021, 21, 175.	3.0	45
54	Estimating global injuries morbidity and mortality: methods and data used in the Global Burden of Disease 2017 study. Injury Prevention, 2020, 26, i125-i153.	2.4	44

#	ARTICLE	IF	CITATIONS
55	Burden of injury along the development spectrum: associations between the Socio-demographic Index and disability-adjusted life year estimates from the Global Burden of Disease Study 2017. <i>Injury Prevention</i> , 2020, 26, i12-i26.	2.4	44
56	Current Insights into Immunology and Novel Therapeutics of Atopic Dermatitis. <i>Cells</i> , 2021, 10, 1392.	4.1	40
57	Spatial, temporal, and demographic patterns in prevalence of chewing tobacco use in 204 countries and territories, 1990â€“2019: a systematic analysis from the Global Burden of Disease Study 2019. <i>Lancet Public Health</i> , The, 2021, 6, e482-e499.	10.0	38
58	Subnational mapping of HIV incidence and mortality among individuals aged 15â€“49 years in sub-Saharan Africa, 2000â€“18: a modelling study. <i>Lancet HIV</i> , the, 2021, 8, e363-e375.	4.7	32
59	Molecular epidemiology of hepatitis C virus genotypes in different geographical regions of Punjab Province in Pakistan and a phylogenetic analysis. <i>International Journal of Infectious Diseases</i> , 2013, 17, e247-e253.	3.3	30
60	Multiepitope Subunit Vaccine Design against COVID-19 Based on the Spike Protein of SARS-CoV-2: An In Silico Analysis. <i>Journal of Immunology Research</i> , 2020, 2020, 1-15.	2.2	29
61	Development of Global Consensus Sequence and Analysis of Highly Conserved Domains of HCV NS5B Protein. [10.5812/hepatmon.6142]. <i>Hepatitis Monthly</i> , 2012, 12, e6142.	0.2	28
62	Phylogenetic analysis of torque teno virus genome from Pakistani isolate and incidence of co-infection among HBV/HCV infected patients. <i>Virology Journal</i> , 2012, 9, 320.	3.4	28
63	Molecular screening of glycyrrhizin-based inhibitors against ACE2 host receptor of SARS-CoV-2. <i>Journal of Molecular Modeling</i> , 2021, 27, 206.	1.8	28
64	Evaluation of prognostic factors for Peg Interferon alfa-2b plus ribavirin treatment on HCV infected patients in Pakistan. <i>Infection, Genetics and Evolution</i> , 2011, 11, 640-645.	2.3	27
65	Awareness and risk factors associated with barbers in transmission of hepatitis B and C from Pakistani population: barberâ€™s role in viral transmission. <i>Asian Biomedicine</i> , 2010, 4, 435-442.	0.3	26
66	Hepatitis B and hepatitis C viruses: a review of viral genomes, viral induced host immune responses, genotypic distributions and worldwide epidemiology. <i>Asian Pacific Journal of Tropical Disease</i> , 2014, 4, 88-96.	0.5	25
67	Zika virus, a pathway to new challenges. <i>Asian Pacific Journal of Tropical Medicine</i> , 2016, 9, 626-629.	0.8	25
68	Designing a multi-epitope vaccine against <i>Mycobacteroides abscessus</i> by pangenome-reverse vaccinology. <i>Scientific Reports</i> , 2021, 11, 11197.	3.3	25
69	Molecular study of HCV detection, genotypes and their routes of transmission in North West Frontier Province, Pakistan. <i>Asian Pacific Journal of Tropical Biomedicine</i> , 2012, 2, 532-536.	1.2	24
70	Mapping inequalities in exclusive breastfeeding in low- and middle-income countries, 2000â€“2018. <i>Nature Human Behaviour</i> , 2021, 5, 1027-1045.	12.0	24
71	Mapping geographical inequalities in oral rehydration therapy coverage in low-income and middle-income countries, 2000â€“17. <i>The Lancet Global Health</i> , 2020, 8, e1038-e1060.	6.3	23
72	RNA dependent RNA polymerase of HCV: A potential target for the development of antiviral drugs. <i>Infection, Genetics and Evolution</i> , 2013, 14, 247-257.	2.3	22

#	ARTICLE	IF	CITATIONS
73	Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients. International Journal of Infectious Diseases, 2012, 16, e597-e602.	3.3	20
74	Estimation of Hepatitis B Virus, Hepatitis C Virus, and Different Clinical Parameters in the Thalassemic Population of Capital Twin Cities of Pakistan. Virology: Research and Treatment, 2015, 6, VRT.S31744.	3.5	18
75	Structure-Based Virtual Screening Identifies Multiple Stable Binding Sites at the RecA Domains of SARS-CoV-2 Helicase Enzyme. Molecules, 2021, 26, 1446.	3.8	18
76	Distribution of hepatitis C virus genotypes, hepatic steatosis and their correlation with clinical and virological factors in Pakistan. Asian Biomedicine, 2010, 4, 253-262.	0.3	18
77	Role of Potash Alum in Hepatitis C virus Transmission at Barber's Shop. Virology Journal, 2011, 8, 211.	3.4	16
78	Polio eradication challenges in Pakistan. Clinical Microbiology and Infection, 2018, 24, 6-7.	6.0	16
79	Effect of interferon plus ribavirin therapy on hepatitis C virus genotype 3 patients from Pakistan: Treatment response, side effects and future prospective. Asian Pacific Journal of Tropical Medicine, 2015, 8, 85-89.	0.8	15
80	A computational study to disclose potential drugs and vaccine ensemble for COVID-19 conundrum. Journal of Molecular Liquids, 2021, 324, 114734.	4.9	15
81	Hepatitis C eradication: A long way to go. World Journal of Gastroenterology, 2015, 21, 12510.	3.3	15
82	Frequency of HEV contamination in sewerage waters in Pakistan. Journal of Infection in Developing Countries, 2010, 4, 842-845.	1.2	15
83	Sequence and Structural Analysis of 3' Untranslated Region of Hepatitis C Virus, Genotype 3a, From Pakistani Isolates. Hepatitis Monthly, 2013, 13, e8390.	0.2	14
84	Transition from millennium development goals to sustainable development goals and hepatitis. Pathogens and Global Health, 2015, 109, 353-353.	2.3	13
85	Elimination of hepatitis from Pakistan by 2030: is it possible?. Hepatoma Research, 2018, 4, 45.	1.5	13
86	Ledipasvir and sofosbuvir: Interferon free therapy for HCV genotype 1 infection. World Journal of Virology, 2015, 4, 33.	2.9	11
87	Epidemiological patterns and risk factors associated with hepatitis B virus in Pakistani population. Asian Biomedicine, 2010, 4, 547-554.	0.3	11
88	Efficacy and Safety of Remdesivir in COVID-19 Positive Dialysis Patients. Antibiotics, 2022, 11, 156.	3.7	11
89	Mutations in the STAT1-interacting domain of the hepatitis C virus core protein modulate the response to antiviral therapy. Molecular Medicine Reports, 2013, 8, 487-492.	2.4	10
90	Pakistan needs to speed up its human immunodeficiency virus control strategy to achieve targets in fast-track acquired immune deficiency syndrome response. World Journal of Virology, 2017, 6, 46.	2.9	10

#	ARTICLE	IF	CITATIONS
91	Rational design of potent anti-COVID-19 main protease drugs: An extensive multi-spectrum in silico approach. <i>Journal of Molecular Liquids</i> , 2021, 330, 115636.	4.9	10
92	Identification of novel silent HIV propagation routes in Pakistan. <i>World Journal of Virology</i> , 2013, 2, 136.	2.9	10
93	Design of a Multi-Epitopes Vaccine against Hantaviruses: An Immunoinformatics and Molecular Modelling Approach. <i>Vaccines</i> , 2022, 10, 378.	4.4	10
94	Potential Immunogenic Activity of Computationally Designed mRNA- and Peptide-Based Prophylactic Vaccines against MERS, SARS-CoV, and SARS-CoV-2: A Reverse Vaccinology Approach. <i>Molecules</i> , 2022, 27, 2375.	3.8	10
95	Evaluation of HIV/AIDS diagnostics kits and formulation of a testing strategy for Pakistan. <i>Journal of Clinical Virology</i> , 2013, 56, 367-369.	3.1	9
96	Prediction and conservancy analysis of promiscuous T-cell binding epitopes of Ebola virus L protein: An in silico approach. <i>Asian Pacific Journal of Tropical Disease</i> , 2016, 6, 169-173.	0.5	9
97	Prevalence of hepatitis C in people who inject drugs in the cities of Rawalpindi and Islamabad, Pakistan. <i>Biomedical Reports</i> , 2017, 7, 263-266.	2.0	9
98	Analyses of ABO blood groups with susceptibility and symptomatic variations of COVID-19 infection, a questionnaire-based survey. <i>Apmis</i> , 2021, 129, 579-586.	2.0	9
99	Ebola in West Africa: an international medical emergency. <i>Asian Pacific Journal of Tropical Biomedicine</i> , 2014, 4, 673-674.	1.2	8
100	Sequence analysis of the L protein of the Ebola 2014 outbreak: Insight into conserved regions and mutations. <i>Molecular Medicine Reports</i> , 2016, 13, 4821-4826.	2.4	8
101	Prediction of promiscuous T cell epitopes in RNA dependent RNA polymerase of Chikungunya virus. <i>Asian Pacific Journal of Tropical Medicine</i> , 2017, 10, 760-764.	0.8	8
102	Modern biotechnology-based therapeutic approaches against HIV infection (Review). <i>Biomedical Reports</i> , 2017, 7, 504-507.	2.0	8
103	Prognostic Role of Monocytic Myeloid-Derived Suppressor Cells in Advanced Non-Small-Cell Lung Cancer: Relation to Different Hematologic Indices. <i>Journal of Immunology Research</i> , 2021, 2021, 1-10.	2.2	8
104	Beneficial Effects of Anticoagulants on the Clinical Outcomes of COVID-19 Patients. <i>Antibiotics</i> , 2021, 10, 1394.	3.7	8
105	The interplay between vitamin D and COVID-19: protective or bystander?. <i>European Review for Medical and Pharmacological Sciences</i> , 2021, 25, 2131-2145.	0.7	8
106	Comparison of Low-Versus High-Dose Steroids in the Clinical Outcome of Hospitalized COVID-19 Patients. <i>Antibiotics</i> , 2021, 10, 1510.	3.7	8
107	Evaluation of the Whole Proteome of <i>Achromobacter xylosoxidans</i> to Identify Vaccine Targets for mRNA and Peptides-Based Vaccine Designing Against the Emerging Respiratory and Lung Cancer-Causing Bacteria. <i>Frontiers in Medicine</i> , 2021, 8, 825876.	2.6	7
108	Predictors of response to antiviral therapy in patients with chronic hepatitis C from Pakistani population. <i>Chinese Medical Journal</i> , 2011, 124, 1333-7.	2.3	7



#	ARTICLE	IF	CITATIONS
109	Progress on global hepatitis elimination targets. World Journal of Gastroenterology, 2021, 27, 8199-8200.	3.3	7
110	Islam and polio. Lancet Infectious Diseases, The, 2014, 14, 791-792.	9.1	6
111	The World after Ebola: An Overview of Ebola Complications, Vaccine Development, Lessons Learned, Financial Losses, and Disease Preparedness. Critical Reviews in Eukaryotic Gene Expression, 2019, 29, 77-84.	0.9	6
112	Familial clustering of hepatitis C virus in a Pakistani population. Journal of Medical Virology, 2020, 92, 3499-3506.	5.0	6
113	Evaluation of Three Rapid Screening Tests for Detection of Hepatitis C Antibodies on Mass Scale. Critical Reviews in Eukaryotic Gene Expression, 2019, 29, 25-28.	0.9	5
114	Role of Therapeutic Plasmapheresis in SARS-CoV-2 Induced Cytokine Release Syndrome: A Retrospective Cohort Study on COVID-19 Patients. International Journal of General Medicine, 2022, Volume 15, 4907-4916.	1.8	5
115	Sequence analysis of hepatitis C virus nonstructural protein 3â€™4A serine protease and prediction of conserved B and T cell epitopes. Biomedical Reports, 2017, 7, 563-566.	2.0	4
116	Clinical outcomes of moderate to severe COVID-19 patients receiving invasive vs. non-invasive ventilation. Asian Pacific Journal of Tropical Medicine, 2021, 14, 176.	0.8	4
117	Effect of Sofosbuvir plus Ribavirin therapy on hepatitis C patients in Pakistan: a retrospective study. PeerJ, 2018, 6, e4853.	2.0	4
118	Computational Evaluation of Abrogation of HBx-Bcl-xL Complex with High-Affinity Carbon Nanotubes (Fullerene) to Halt the Hepatitis B Virus Replication. Molecules, 2021, 26, 6433.	3.8	4
119	Predictors of Therapeutic Outcome to Nucleotide Reverse Transcriptase Inhibitor in Hepatitis B Patients. Viral Immunology, 2018, 31, 632-638.	1.3	3
120	Possible Role of Regulatory B Cells in Different Behçet's Disease Phenotypes and Therapies: First Report from Egypt. Journal of Inflammation Research, 2021, Volume 14, 737-744.	3.5	3
121	Burden of Transport-Related Injuries in the Eastern Mediterranean Region: A Systematic Analysis for the Global Burden of Disease Study 2017. Archives of Iranian Medicine, 2021, 24, 512-525.	0.6	2
122	In silico identification of BIM-1 (2-methyl-1H-indol-3-yl) as a potential therapeutic agent against elevated protein kinase C beta associated diseases. African Journal of Biotechnology, 2012, 11, .	0.6	2
123	Correlation of Apolipoprotein B mRNA-editing Enzyme, Catalytic Polypeptide- like 3C Genetic Variant rs8177832 with HIV-1 Predisposition in Pakistani Population. Current HIV Research, 2019, 16, 297-301.	0.5	2
124	Annotation of Potential Vaccine Targets and Design of a Multi-Epitope Subunit Vaccine against Yersinia pestis through Reverse Vaccinology and Validation through an Agent-Based Modeling Approach. Vaccines, 2021, 9, 1327.	4.4	2
125	Immunoinformatic Approach to Conceive a Next Generation Multi-Epitope Vaccine Against Achromobacter xylosoxidans Infections. Frontiers in Medicine, 0, 9, .	2.6	2
126	Sequence comparison and phylogenetic analysis of Hepatitis C virus genotype 3 polymerase. Molecular Medicine Reports, 2014, 9, 1266-1270.	2.4	1



#	ARTICLE	IF	CITATIONS
127	Recent advances on Ebola virus. Asian Pacific Journal of Tropical Disease, 2017, 7, 65-67.	0.5	1
128	Prediction of promiscuous epitopes in NSP2 of Chikungunya virus: An in-silico approach. Tropical Biomedicine, 2020, 37, 566-577.	0.7	1
129	An in silico study to unveil potential drugs and vaccine chimera for HBV capsid assembly protein: combined molecular docking and dynamics simulation approach. Journal of Molecular Modeling, 2022, 28, 51.	1.8	1
130	Mapping the effect of drugs on ACE2 as a novel target site for COVID-19 therapy. European Review for Medical and Pharmacological Sciences, 2021, 25, 3923-3932.	0.7	1
131	SARS-CoV-2 associated pathogenesis, immune dysfunction and involvement of host factors: a comprehensive review.. European Review for Medical and Pharmacological Sciences, 2021, 25, 7526-7542.	0.7	1
132	Scavenger receptor class-A plays diverse role in innate immunity, cell signaling and different pathologies. Asian Pacific Journal of Tropical Disease, 2016, 6, 567-572.	0.5	0
133	Risk of Malignancy in Breast FNAB Categories, Classified According to the Newly Proposed International Academy of Cytology (IAC) Yokohama System. Cancer Management and Research, 2022, Volume 14, 1693-1701.	1.9	0